Kevin joined Sequent in January 2014, and brings more than 30 years of experience in public accounting and senior financial executive roles, primarily with medical device companies. From September 2010 to December 2012, Kevin served as the VP of Finance & CFO with Neomend, Inc. Neomend developed and commercialized a novel hydrogel surgical sealant used in minimally invasive and laparoscopic thoracic procedures. Experiencing rapid revenue growth, the company was acquired by the Davol Division of CR Bard in October of 2012.
Prior to Neomend, Kevin served as the VP of Finance & CFO for SenoRx, Inc. from 2001 to 2010. SenoRx designed, developed, manufactured and marketed minimally invasive devices for the diagnosis and treatment of breast cancer. The company completed its Initial Public Offering (IPO) in March of 2007 and was acquired by CR Bard in July 2010.
Prior to SenoRx, Kevin served in a variety of financial leadership roles at various companies, including Biopsys Medical (acquired by J&J). Kevin began his public accounting career in 1977 with KPMG, after earning his B.A. in Business Administration from California State University, Fullerton. He earned his CPA certification in 1980 and holds a Master Degree in Taxation from Golden Gate University.